GAMIDA CELL said FDA has granted Breakthrough Therapy Designation to the company’s lead product candidate, NiCord, in development as a novel graft modality for bone marrow transplantation in patients with high risk hematological malignancies. The international, multi-center phase III registration study of NiCord is planned to begin before the end of the year, the company...
A curious piece of paper hangs in a frame outside the director’s office at University of Iowa Holden Comprehensive Cancer Center on the second floor of the General Hospital.
